RemeGen Co (HKSE:09995) Price-to-Tangible-Book : 4.57 (As of May. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Price-to-Tangible-Book?

As of today (2024-05-14), RemeGen Co's share price is HK$30.25. RemeGen Co's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$6.62. Hence, RemeGen Co's Price to Tangible Book Ratio of today is 4.57.

The historical rank and industry rank for RemeGen Co's Price-to-Tangible-Book or its related term are showing as below:

HKSE:09995' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.55 Med: 7.45 Max: 11.04
Current: 4.57

During the past 6 years, RemeGen Co's highest Price to Tangible Book Ratio was 11.04. The lowest was 4.55. And the median was 7.45.

HKSE:09995's Price-to-Tangible-Book is ranked worse than
70.08% of 1220 companies
in the Biotechnology industry
Industry Median: 2.71 vs HKSE:09995: 4.57

A closely related ratio is called PB Ratio. As of today, RemeGen Co's share price is HK$30.25. RemeGen Co's Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$6.91. Hence, RemeGen Co's P/B Ratio of today is 4.38.

RemeGen Co Price-to-Tangible-Book Historical Data

The historical data trend for RemeGen Co's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Price-to-Tangible-Book Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

11.04

9.16

5.73

5.66

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial									5.73	3.99	-	5.66	-

Competitive Comparison of RemeGen Co's Price-to-Tangible-Book

For the Biotechnology subindustry, RemeGen Co's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Price-to-Tangible-Book falls into.

RemeGen Co Price-to-Tangible-Book Calculation

RemeGen Co's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	30.25	/	6.619
	=	4.57

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

RemeGen Co Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines